Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 1674330A

Next Previous
Drug Profile

GSK 1674330A

Alternative Names: GSK-1674330A; HPV-16/18/33/58 tetravalent vaccine; Human papillomavirus (types 16, 18, 33, 58) L1 virus-like particle vaccine - GSK; Human papillomavirus (types 16, 18, 33, 58) L1 VLP vaccine - GSK; Human papillomavirus quadrivalent (types 16, 18, 33, 58) recombinant vaccine - GSK; Tetravalent HPV L1 16/18/33/58 virus-like particle vaccine - GSK

Latest Information Update: 18 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 24 Mar 2014 Final efficacy and adverse events data from a phase I/II trial in Human papillomavirus infections (prevention) published in Vaccine
  • 01 Feb 2014 Discontinued - Phase-I for Human papillomavirus infections in Belgium (IM)
  • 01 Feb 2014 Discontinued - Phase-I/II for Cervical cancer in Belgium (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top